Posted by Michael Wonder on 27 Jun 2023
Olaparib in combination with bevacizumab for the maintenance treatment of adults with advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
27 June 2023 - The Department of Health and Social Care has asked the NICE to review its guidance on the use of olaparib in combination with bevacizumab in the NHS in England (TA693).
Olaparib, when used in combination with bevacizumab, is not recommended for maintenance treatment of adults with high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer:
- Has completely or partially responded after first-line platinum-based chemotherapy with bevacizumab
- Is advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4)
- Is homologous recombination deficiency positive (defined as having either a BRCA1 or BRCA2 mutation or genomic instability)
